
More measles cases and exposures confirmed in B.C.
B.C.'s measles caseload has risen again.
The B.C. Centre for Disease Control reported a total of 63 confirmed measles cases in the province in its latest update Thursday afternoon.
That's an increase of 14 from the 49 reported on Tuesday, with most of the latest cases detected in the Northern Health region.
A total of 41 measles infections have been confirmed in Northern Health in 2025 so far, compared to single-digit totals in the mainland's other regional health authorities and none on Vancouver Island.
The Northern Health total is considered an undercount, because 'some communities have a large disease burden, and not everyone is presenting to Northern Health for diagnosis and health care support,' according to the BCCDC.
The latest update also included several new public exposure notices.
Such notices are issued when health officials are unable to directly contact everyone who may have been exposed to a known case of the virus at a given place and time. The latest exposure notices include several flights and airports, as well as a spa and a sports complex in Kamloops.
Newly published exposures include:
June 17
Son Mai Spa, 459 Lansdowne St., Kamloops, from 11 a.m. to 1:45 p.m.
June 19
Andersen's Sewing, 213 - 141 Victoria St., Kamloops, from 1 p.m. to 3:10 p.m.
June 21
McArthur Island Sport and Event Centre, upper floor field, 1665 Island Pkwy., Kamloops, from 1 p.m. to 3:45 p.m. and 5 p.m. to 7:30 p.m.
June 23
WestJet flight WS320 from Fort St. John to Vancouver, departed at 12:44 p.m. MDT, and arrived at 2:44 p.m. PDT
WestJet flight WS332 from Vancouver to Kelowna, departed at 6:18 p.m. and arrived at 7:17 p.m.
North Peace Regional Airport (YXJ) from 10 a.m. to 2:30 p.m. MDT
Vancouver International Airport (YVR) – Terminal B, from 2:45 p.m. to 8:30 p.m.
Kelowna International Airport (YLW) from 7:20 p.m. to 9:40 p.m.
June 25
WestJet flight WS3540 from Kamloops to Calgary, departed at 5:38 a.m. PDT, and arrived at 8 a.m. MDT
Kamloops Airport (YKA) from 4 a.m. to 7:50 a.m.
Anyone who may have been exposed to measles should monitor for symptoms, which include 'fever, cough, runny nose, and red and inflamed eyes that are often sensitive to light,' according to the BCCDC.
'These symptoms are followed by a rash, which starts first on the face and neck, and spreads to the chest, arms and legs.'
Measles is a highly contagious disease that spreads easily through the air, and symptoms can develop between seven and 21 days after exposure. Those who are completely unvaccinated against the virus – including children under one year old – are at greatest risk.
Most people in Canada are immune to measles due to vaccination or previous infection. However, the prevalence of the disease has been increasing in recent years as vaccination rates have dropped.
In B.C., the vaccination rate among seven-year-olds was 72.4 per cent in 2023, the latest year for which data is available. That's down from a rate of 90.9 per cent a decade earlier.
On Wednesday, Premier David Eby described this year's measles surge as 'the sadly predictable outcome' of the 'recklessness' of politicians who question vaccine safety.
'I will encourage all British Columbians to ensure that they are vaccinated,' Eby said. 'Measles is no joke. It kills kids. It's a preventable disease, and we don't want that to be the story of the summer for our province.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

National Post
11 minutes ago
- National Post
Predictmedix AI Expands into Mobile Diagnostics with New AI-Driven Diabetes Screening Platform
Article content TORONTO — Predictmedix AI Inc. (CSE: PMED | OTC: PMEDF | FRA: 3QP), a leader in artificial intelligence-driven health screening solutions, is expanding into the direct-to-consumer market with a mobile solution designed to deliver rapid, non-invasive diabetic screening — with India identified as the initial launchpad for this transformative initiative. Leveraging the company's proprietary AI technology, the platform is intended to empower millions with instant access to diabetic risk assessments using only a smartphone, eliminating the need for blood draws, lab visits, or clinical infrastructure. Article content By combining advanced facial and biometric analysis with seamless smartphone delivery, the solution brings accessible, affordable, and scalable diabetic screening to some of the most underserved populations across India. This milestone represents a significant step in Predictmedix AI's broader vision to reshape global healthcare delivery and accelerate the adoption of AI-enabled, mass-scale preventive health solutions. Article content 'We are addressing a critical gap in healthcare access with a cutting-edge solution that empowers individuals to take control of their health using the device they already own — their mobile phone,' said Dr. Rahul Kushwah, COO of Predictmedix AI. 'India has over 100 million diabetics and a significant number remain undiagnosed. Our app is designed to bridge that diagnostic divide.' Article content Key Features: Article content Instant Diabetic Risk Scoring via smartphone. AI-driven facial and biometric analysis based on Predictmedix's proven non-invasive screening platform. User-friendly design with multilingual support for broad accessibility. Secure, privacy-compliant data handling, in line with India's Digital Personal Data Protection (DPDP) Act. Article content Strategic Significance: Article content India's diabetes epidemic is accelerating, with estimates projecting nearly 1 in 3 adults to be diabetic or prediabetic by 2045. Simultaneously, smartphone adoption now exceeds 1.1 billion users — a convergence that creates a once-in-a-generation opportunity for mobile-first, AI-powered health solutions. Article content Our platform is uniquely positioned to: Article content Generate recurring revenue streams through direct-to-consumer and B2B channels. Article content Details of the company's recent product validations, pilot programs, and strategic partnerships can be found in earlier press releases available at: About Predictmedix AI Inc. Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA:3QP) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company's Safe Entry Stations – powered by a proprietary artificial intelligence (AI) – use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including 19 physiological vital parameters, impairment by drugs or alcohol, fatigue, or various mental illnesses. Predictmedix AI's proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at or follow us on Twitter, Instagram or LinkedIn. Article content Caution Regarding Forward-Looking Information: This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the 'U.S. Securities Act'), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or 'U.S. Persons', as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any Page 4 of 4 future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the Company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry. Article content All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law. Article content Disclaimer: The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time. Article content Article content Article content Article content Article content Article content

National Post
an hour ago
- National Post
Kardium Announces $250M (CA$340M) Financing to Launch Innovative Atrial Fibrillation Treatment
Article content VANCOUVER, British Columbia — Kardium Inc., the developer of the Globe ® Pulsed Field System – an innovative treatment for atrial fibrillation (AF) – has raised US$250 million in a new financing round. Article content Article content The oversubscribed round was led by new investors including Janus Henderson Investors, Qatar Investment Authority (QIA), MMCAP, Piper Heartland Healthcare Capital, Eventide Asset Management, and Eckuity Capital. Existing investors also participated, including funds and accounts advised by T. Rowe Price Associates, Inc., T. Rowe Price Investment Management, Inc., and Durable Capital Partners LP. The financing also includes an equity investment from a leading strategic investor. Article content 'We're thrilled to have secured this transformational financing with a world-class syndicate of investors,' said Kevin Chaplin, CEO of Kardium. 'This funding enables us to move ahead with the commercial launch of the Globe System by expanding our manufacturing capabilities and building a strong commercial team. Everyone at Kardium is energized by the opportunity to bring the Globe System to market and help improve the lives of millions of patients worldwide suffering from atrial fibrillation.' Article content 'We are delighted to join Kardium as an investor,' said Aaron Schaechterle, Portfolio Manager at Janus Henderson Investors. 'The Globe System is a disruptive innovation with exemplary clinical outcomes that has the potential to improve the lives of patients with atrial fibrillation. This is a pivotal moment in the evolution of AF treatment, as the field transitions toward pulsed field ablation, and we are proud to help support the introduction of Kardium's groundbreaking technology to the market.' Article content Impressive clinical data from the pivotal PULSAR clinical study of the Globe System was recently presented at the 2025 Heart Rhythm Society annual meeting. This data demonstrated remarkable results with the Globe System, showing freedom from atrial arrhythmia at 1 year of 78% in paroxysmal AF patients, with 0% device-related primary safety events. i The new funding will enable Kardium to pursue regulatory approvals for the Globe System, further expand its manufacturing facilities and production capacity, and establish a clinical support and commercial team in preparation for the anticipated commercial launch of the Globe System later this year. It will also enable Kardium to run further clinical research for additional applications and expanded indications for the Globe System. Article content The Globe Pulsed Field System consists of a sophisticated catheter with a 122-electrode array and advanced software that enables rapid pulmonary vein isolation, high-definition mapping, and the ability to ablate anywhere in the atrium – all with a single catheter. Article content About Kardium Article content Kardium Inc. ( is a rapidly growing, privately held medical solutions company that has developed an advanced system for atrial fibrillation (AF) treatment: the Globe System. Kardium has built an outstanding team, who have worked with top medical advisors to develop the Globe System. Founded in 2007 and headquartered in Vancouver, Canada, Kardium has consistently ranked as one of the top companies to work for in British Columbia. Article content This press release may contain forward-looking statements, which reflect current expectations regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, performance or achievements to be materially different from those expressed or implied by such statements. The Globe System is restricted by federal law to investigational use only, and it has not been approved or cleared for commercial distribution in any jurisdictions. Article content Article content Article content Article content

National Post
an hour ago
- National Post
WSIB Quietly Outsources Union Work During Strike, Union Says
Article content TORONTO — The Ontario Compensation Employees Union (OCEU/CUPE 1750) is raising the alarm after internal documents reveal the Workplace Safety and Insurance Board (WSIB) has begun outsourcing core work performed by striking frontline workers. Article content An internal message sent to WSIB staff outlines a trial program that allows contracted health-care providers to contact employers directly and discuss injured workers' functional abilities — a role typically performed by Return-to-Work Specialists. Article content 'This is a blatant attempt to undermine the strike and outsource union jobs behind closed doors,' said Harry Goslin, president of OCEU/CUPE 1750. 'WSIB would rather contract out work than come to the table with a fair deal. That's not just disrespectful to our members — it's dangerous for injured workers who rely on experienced, specialized support.' Article content According to the memo, the contractors will: Article content Call employers after each comprehensive assessment to share functional abilities. Discuss return-to-work options such as modified duties or alternate work. Confirm alignment between current job duties and medical limitations. Article content 'These decisions affect people's recovery, their employment and their future,' said Goslin. 'Offloading this to private contractors with no accountability is irresponsible.' Article content The union is calling on WSIB to immediately halt the trial and return to the bargaining table. Article content The strike, now close to its third month involves more than 3,000 WSIB workers across Ontario, including case managers, return-to-work specialists, and support staff. Workers are seeking fair wages and workload protections to ensure quality service for injured workers. Article content Article content Article content Article content Contacts Article content For more information, please contact: Article content Article content Article content Article content